Potential mechanisms of hormone resistance in prostate cancer
The events which characterize the progression from the hormone dependent to the hormone independent state in prostate cancer remains unclear ( Figure 1) . One of the central questions in the study of androgenindependent prostate cancer concerns the point at which androgen-independent cells arise. Two main theories have been proposed. The first theory suggests that androgen independence arises as a consequence of androgen deprivation therapy. This approach proposes that prostate cancer begins as a collection of androgen-dependent cells and only as a result of androgen deprivation do androgen-resistant cells arise. This mechanism of resistance is analogous to bacteria gaining resistance to antimicrobials. The second approach suggests that androgen resistant cells are present at diagnosis. In this case, androgen deprivation creates an environment that allows only the proliferation of androgen-resistant cells which eventually become the dominant cell type [2] .
This second approach has been validated with experimental evidence from two animal models. Isaacs and Coffey demonstrated in a series of experiments using the Dunning 3327-H adenocarcinoma model that selective growth of androgen-resistant cells already present at the initiation of androgen depletion is the mechanism for the development of androgen resistance [2] . They hypothesized that if a tumor is initially composed of a heterogeneous population of cells in terms of androgen sensitivity, then random tumor tissue samples would demonstrate a varied growth pattern when implanted into castrated animals. On the other hand, if the tumor is composed of only androgen-sensitive cells which through adaptation became androgen resistant, the growth rates would be similar. They found a tremendous variation in the growth rates of the implanted samples, suggesting the original tumor was initially heterogeneous in terms of androgen sensitivity. Further evidence that supports this is the development of the transgenic mouse prostate adenocarcinoma model (TRAMP) [3] . TRAMP mice spontaneously develop high-grade prostate intraepithelial neoplasia and welldifferentiated prostate cancer by 10-12 weeks. Sixtyfive percent of mice castrated at 12 weeks of age demonstrated an initial reduction followed by a rapid regrowth of an androgen-independent tumor [4] . This rapid regrowth again supports the concept that the Figure 1 . Genetic progression of prostate cancer carcinogenesis. The postulated progression of a normal prostate epithelium to an androgen independent invasive phenotype. Chromosomal alterations, induction of oncogenes, loss/mutation of tumor suppressor genes, increased availability of adrenal steroids, loss of growth inhibiting neutral endopeptidase 24.11 (NEP) and genetic mutation/amplification/abnormal activation of androgen receptor (AR) are indicated.
tumor is initially heterogeneous in terms of androgen sensitivity.
The role of the androgen receptor
Androgens (testosterone and dihydrotestosterone) exert their actions by binding to the androgen receptor (AR). This receptor complex undergoes phosphorylation and dimerization to become an activated complex which is now capable of binding tightly to specific DNA sequences (termed androgen response elements or AREs). Once bound to DNA, this complex facilitates the formation of a preinitiation complex on the promoter of target genes and enhances transcription. The induction of these target genes can then lead to translation of new proteins which may initiate some biological response (i.e. growth).
The role of androgen receptor (AR) gene mutations in the progression of prostate cancer to a hormone independent state has been more widely studied than any other molecular mechanism [5] . The AR protein can be divided into three regions: the amino terminal domain, which affects transcriptional efficiency; a central DNA binding domain, which binds to the ARE upstream of target genes; and the hormone binding domain [6] . Many of the mutations found in the AR gene target the hormone binding region (reviewed in [5] [6] [7] ). Whereas increased transcriptional activity is only observed when the wildtype AR protein is bound to androgens, many of these mutated receptors have the ability to increase transcriptional activity when bound to other steroid hormones such as progestins, estrogens or even antiandrogens (reviewed in [5, 6] ). This would enable the tumor cells to utilize the androgen receptor machinery for induction of growth by responding to other endogenous steroid hormones. This is of direct clinical concern, as prescribing standard anti-androgen therapy to patients with mutations in the AR gene, may allow for transcriptional activation by anti-androgens and could be detrimental to their treatment [8] . It should be noted, however, that although there is substantial evidence demonstrating mutations of the AR gene, the frequency and role of these mutations remains unclear. There has been speculation that AR mutations may characterize a more aggressive disease or confer the ability of hormone independence [6] . However, as there have been a number of studies demonstrating no mutations in the AR gene of patients with hormone refractory prostate cancer, the current evidence does suggest that not all hormone-independent cancers contain AR gene mutations.
AR gene expression has been examined by a number of groups both in vitro and in vivo [7, [9] [10] [11] [12] . Initial studies using the Dunning rat prostate adenocarcinoma model and the human prostate cancer cell lines DU145 and PC3 suggested a decrease in both AR mRNA and protein levels [9, 10] . More recent studies, however, contradict these findings. AR protein has been detected immunohistochemically in the majority of human prostate cancers, regardless of disease state [11, 12] . Androgen ablation therapy does not appear to significantly change the pattern of AR expression, suggesting that failure of androgen ablation therapy is not due to the selection of AR-negative tumor cells [11, 12] . Moreover, a study by Visakorpi and colleagues has demonstrated that a common genetic alteration in hormone refractory, locally recurrent prostate cancers was an amplification of the chromosomal region Xq11-12, which coincides with the location of the androgen receptor gene [5, 13] . Further studies demonstrated a 2.7 to 28 fold amplification in 15 out of 54 locally recurrent tumors, whereas no amplification was observed in the primary tumors examined [5, 13] . These results suggest that perhaps many recurrent prostate tumors may not be androgen independent as previously thought, but may have acquired an increased capacity, due to the increased number of receptors, to utilize residual androgens which remain after ablation therapy [5] .
Increased availability of androgens
Another mechanism which could allow for growth of prostate tumor cells after androgen ablation therapy involves the increased availability of adrenal steroids in the prostate [5] . It has been demonstrated that although castration-induced androgen deprivation causes a 95% loss in serum testosterone, the concentration of dihydrotestosterone (DHT) in prostate tissue is only reduced by 60% [14] . It is possible that after androgen ablation therapy there is an increased conversion of adrenal steroids to active androgens, which would allow for androgen-dependent growth of the tumor. The combination of traditional endocrine therapy (gonadotropin hormone releasing hormone agonists, estrogens or surgical castration) and anti-androgen therapy (flutamide, nilutamide or bicalutamide) which would block androgen production in peripheral tissues has been suggested as the most effective therapy. Current clinical evidence, however, gives only minimal support of the benefit of maximum androgen blockage therapy [15] .
Differential gene expression
There are a number of groups which are examining the genetic differences between hormone-dependent and hormone-independent prostate cancers [16] [17] [18] [19] . Although there have been a number of differences found, the identity and mechanism of many of these genes are unknown [16] [17] [18] [19] . One recent finding by Papandreou and colleagues, however, demonstrated the loss of expression of neutral endopeptidase 24.11 (NEP) in hormone refractory cancers. NEP is a cellsurface enzyme expressed by prostatic epithelial cells that cleaves and inactivates neuropeptides such as neurotensin, bombesin and endothelin-1, all which have been implicated in the growth of androgen-dependent prostate cancer [20] [21] [22] [23] . NEP appears to be diminished in androgen-independent prostate cancer cell lines and in the majority (78%) of metastatic prostate cancer specimens examined [20] . Androgen ablation therapy would allow an increase in the bioavailability of mitogenic neuropeptides, suggesting another mechanism for growth of hormone refractory prostate cancer [20] .
Many of the androgen mediated growth processes appear to be the result of the secretion of local paracrine factors by the prostatic stroma [24] . There is substantial evidence demonstrating the increased expression of growth factors, their receptors and binding proteins during the progression of prostate cancer [5, [25] [26] [27] [28] [29] . Members of the fibroblast growth factor (FGF) and insulin-like growth factor (IGF) families as well as transforming growth factor α and keratinocyte growth factor, have been shown to activate the AR signaling pathway in the absence of androgens (reviewed in [5] ). Transforming growth factor β has also been shown to be overexpressed in more advanced tumors, suggesting an aberrant activity for this growth factor (reviewed in [8] ). Finally, there is increasing evidence that AR can be activated in the absence of androgens by ligandindependent phosphorylation of the AR through the protein kinase A signaling pathway [30] .
Alternative mechanisms
There are many other alternative mechanisms which may contribute to prostate tumor cells no longer requiring androgens for growth. For instance, steroids interact with a number of accessory factors to bring about optimal transcription of target genes. The ARA-70 protein has been shown to be a specific coactivator of the AR complex, enhancing transcription by a factor of ten [31] . Under appropriate conditions this transcription factor may allow activation of androgen specificgrowth enhancing genes in the absence of androgens.
Alternatively, androgen withdrawal causes regression of prostate cells by triggering the apoptotic pathway [32] . Bcl-2, a protein which inhibits apoptosis, has been shown to increase in prostate cancer [33] [34] [35] . Androgen-independent tumors demonstrate a much higher level of expression of bcl-2 protein [35] . This increase in bcl-2 levels may create an apoptosisresistant cell population which is capable of androgenindependent growth.
Finally, the p53 tumor suppressor gene is believed to be a negative regulator of cell growth [36, 37] . p53 mutations appear to be a late event in the progression of prostate cancer, with tumors of higher grade and stage demonstrating a higher frequency of mutations of this gene. Also, it has been demonstrated that androgen-independent tumors have a high degree of p53 mutations [36] . Whether these mechanisms contribute to the growth of androgen-independent tumors remains to be seen.
Current treatments for hormone refractory prostate cancer (HRPC)
Prostate cancer that progresses in the presence of androgen blockade (i.e. castrate levels of testosterone) is defined as hormone refractory prostate cancer (HRPC). No effective 'standard' chemotherapy exists for these patients, in which median survival is 6-9 months [38] . The National Comprehensive Cancer Network (NCCN), an organization of cancer centers around the country, recently updated its practice guidelines for the treatment of patients with HRPC [39] . These guidelines, for patients managed outside of experimental protocol, list three different categories of care: supportive care with prednisone, palliative chemotherapy and/or systemic radiation (Table 1) .
Supportive care
As clinical trials have yet to demonstrate a therapeutic combination which has been shown to definitively increase survival, a reasonable alternative to other treatments of HRPC is supportive care. Supportive care should consist of rigorous pain management, symptom control and include active hospice care [40] . Prednisone and other glucocorticoids have frequently been used to manage symptoms in patients who have advanced prostate cancer with a number of studies documenting improved symptom control and increased quality of life in treated patients [41] [42] [43] . Concomitantly, the role of bisphosphonates in palliating bone pain is also beginning to be appreciated [44] .
Chemotherapy
Chemotherapy is an option in the treatment of advanced prostate cancer. The NCCN guidelines recommend several regimens that can be used (Table 1) . Briefly, the first regimen consists of ketoconazole and doxorubicin. This combination has been evaluated in a phase II trial with patients whose disease had progressed following initial hormone therapy (results summarized in Table 1 ) [45] . Complications included the development f PSA response refers to percentage of patients who experienced a greater than 50% decrease in serum prostate specific antigen levels.
g NA -not applicable as palliative endpoints were measured. of significant acral erythema and stomatitis in 29% of patients and an overall 45% hospitalization rate. The combination of vinblastine and estramustine is another chemotherapeutic approach in the treatment of HRPC. While vinblastine alone yields minimal response as a single agent in HRPC, the combination with estramustine has demonstrated synergistic effects in both preclinical and clinical studies (clinical data summarized in Table 1 ) [46] [47] [48] [49] [50] . The therapy appears to be well tolerated with minimal complications.
The third regimen utilizes a combination of estramustine and etoposide. Both these agents exert an effect through the nuclear matrix [51] . Both in vitro and in vivo preclinical studies demonstrate that the combination of these agents was more effective than either agent alone [51] . These studies formed the basis for several clinical trials [52] [53] [54] . Combined results of three trials (with lower doses of estramustine in each consecutive trial) demonstrated soft tissue responses in 45-53% of patients; PSA declines of greater than 50% in 39-58% and a median survival of 52-56 weeks. Estramustine can cause significant nausea with the regimen reported to be more tolerable in the two trials with decreased estramustine doses [53, 54] .
A fourth regimen combines estramustine with paclitaxel. While both of these agents demonstrate antimicrotubule activity, each possess different mechanisms of action. While clinical studies with paclitaxel alone proved disappointing [55] , the combination of paclitaxel with estramustine demonstrated synergistic responses in both preclinical and clinical studies (Table 1) [56] [57] [58] . Preliminary analysis of a phase II trial combining estramustine and etoposide with paclitaxel (135 mg/m 2 over 3 h on day 2) showed an improved response compared to estramustine and etoposide alone and similar response to the results obtained with the combination of paclitaxel and estramustine [59, 60] .
The fifth regimen is a combination of the semisynthetic doxorubicin-derivative mitoxantrone with prednisone. Preliminary clinical studies with mitoxantrone alone demonstrated modest activity with the drug being well tolerated [61, 62] . These observations led to two trials of mitoxantrone in HRPC in which palliative endpoints were used as response criteria [63, 64] . One trial compared the combination of mitoxantrone with prednisone with prednisone alone (Table 1 ) [64] . Twenty-nine percent of the patients in the mitoxantrone-prednisone arm achieved the defined palliative endpoints whereas only 12% of the patients in the prednisone arm reported these responses [64] . Patients who demonstrated a response had significant improvement in quality of life scales measuring overall well-being.
Radiotherapy
The majority of patients with HRPC do not have softtissue disease. Rather they experience bone metastases. Autopsy studies conducted on patients with advanced prostate cancer have documented the frequency of bone metastasis at being 65-85% [65] . The hallmark of skeletal metastasis is pain. The main goal of therapy for these patients is symptom control. Standard external-beam radiation therapy, which has been shown to be effective in controlling symptoms in a regionally treated area, is not a likely treatment option for patients with diffuse bone metastases. Injectable radioisotopes have been investigated. Phosphorous 32 was shown to be effective in achieving pain relief; however, significant bone marrow depression limited its clinical use (Table 1) [66] . More promising is the use of strontium-89, which localizes preferentially to sites of osteoblastic activity. This minimizes the myelosuppressive effect of therapy. Strontium-89 has been tested in a number of clinical trials with promising results [67] [68] [69] [70] [71] . Patients reported symptom relief, as well as increased mobility and improved quality of life [67] [68] [69] [70] [71] .
Conclusions
Androgen resistance is the inevitable outcome for prostate cancer that is treated with androgen deprivation. The switch to an androgen resistant phenotype appears to be the result of the growth of resistant cells already present at the initiation of therapy. This phenotype has been associated with multiple changes at the molecular level. None of these alterations, however, have been universally demonstrated in hormone refractory tumors. Most likely it is the accumulation, as well as the yet to be described synergism, of these and other genetic alterations that lead to the androgen resistant phenotype. Treatment regimens for this disease are promising. Currently, there are practical, effective and tolerable regimens for HPRC available. Many regimens (too numerous to be discussed here) are currently being tested in preclinical and clinical settings with promising results. Hopefully, these approaches will soon provide new and improved treatments for patients with hormone refractory prostate cancer.
